Exclusive Summary

• - Core patents have expired and the drug is not approved in US/EU; many LMICs remain whitespace, enabling first-in/differentiated PPI positioning.
• - As an IV PPI, it serves hard hospital needs (UGIB, ICU/post-op, NPO patients) and aligns with multi-country guideline practices.
• - Pharmacologic advantages (longer half-life, less CYP2C19 dependence, better nocturnal acid control) are compelling in Asian populations with high CYP2C19 polymorphism.
• - Large demand pool: ~1.0–1.2 billion with GERD globally and millions of UGIB hospitalizations annually sustain steady inpatient usage.
• - Cost-competitive vs originator IV PPIs (≈20–60% savings) with ATC A02BC11 aiding tender classification and reimbursement access.

Asset Materials

Contact Us for Full Materials